Figure 3.

A scheme of CRISPR-Cas9 engineering in the allogenic CAR-T therapy. T cells are extracted from healthy donors and engineered with CRISPR-Cas9 technology to edit select genes including genes for TCR, PD1, and MHC Class I and II molecules, among others. Later, CAR is randomly inserted into the genome via lentivirus or precisely inserted at a target locus via the CRISPR-Cas9 system to create an engineered allogenic off-the-shelf CAR-T cell. These donor-derived allogenic CAR-T cells are manufactured in scale and given back to multiple cancer patients.